JLE

Epileptic Disorders

MENU

From here to epilepsy: the risk of seizure in patients with Alzheimer's disease Volume 18, numéro 1, March 2016

  • [Abraham et al., 2009] Abraham H., Veszpremi B., Kravjak A., Kovacs K., Gomori E., Seress L. Ontogeny of calbindin immunoreactivity in the human hippocampal formation with a special emphasis on granule cells of the dentate gyrus. Int J Dev Neurosci. 2009;27:115-127.
  • [Amatniek et al., 2006] Amatniek J.C., Hauser W.A., DelCastillo-Castaneda C. Incidence and predictors of seizures in patients with Alzheimer's disease. Epilepsia. 2006;47:867-872.
  • [Arroyo and Kramer, 2001] Arroyo S., Kramer G. Treating epilepsy in the elderly: safety considerations. Drug Saf. 2001;24:991-1015.
  • [Bartfai et al., 2007] Bartfai T., Sanchez-Alavez M., Andell-Jonsson S. Interleukin-1 system in CNS stress: seizures, fever, and neurotrauma. Ann N Y Acad Sci. 2007;1113:173-177.
  • [Belcastro et al., 2007] Belcastro V., Costa C., Galletti F., Pisani F., Calabresi P., Parnetti L. Levetiracetam monotherapy in Alzheimer patients with late-onset seizures: a prospective observational study. Eur J Neurol. 2007;14:1176-1178.
  • [Bell et al., 2011] Bell J.S., Lönnroos E., Koivisto A.M. Use of antiepileptic drugs among community-dwelling persons with Alzheimer's disease in Finland. J Alzheimers Dis. 2011;26:231-237.
  • [Bernardi et al., 2010] Bernardi S., Scaldaferri N., Vanacore N. Seizures in Alzheimer'sdisease: a retrospective study of a cohort of outpatients. Epileptic Disord. 2010;12:16-21.
  • [Born et al., 2014] Born H.A., Kim J.Y., Savjani R.R. Genetic suppression of transgenic APP rescues hypersynchronous network activity in a mouse model of Alzeimer's disease. J Neurosci. 2014;34:3826-3840.
  • [Butler and Zeman, 2008] Butler C.R., Zeman A.Z. Recent insights into the impairment of memory in epilepsy: transient epileptic amnesia, accelerated long-term forgetting and remote memory impairment. Brain. 2008;131:2243-2263.
  • [Butler et al., 2013] Butler C., van Erp W., Bhaduri A., Hammers A., Heckemann R., Zeman A. Magnetic resonance volumetry reveals focal brain atrophy in transient epileptic amnesia. Epilepsy Behav. 2013;28:363-369.
  • [Cabrejo et al., 2006] Cabrejo L., Guyant-Marechal L., Laquerriere A. Phenotype associated with APP duplication in five families. Brain. 2006;129:2966-2976.
  • [Cheng et al., 2015] Cheng C.H., Liu C.J., Ou S.M. Incidence and risk of seizures in Alzheimer's disease: a nationwide population-based cohort study. Epilepsy Res. 2015;115:63-66.
  • [Chin, 2011] Chin J. Selecting a mouse model of Alzheimer's disease. Methods Mol Biol. 2011;670:69-89.
  • [Chin et al., 2005] Chin J., Palop J.J., Puolivali J. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2005;25:9694-9703.
  • [Cloyd et al., 2006] Cloyd J., Hauser W., Towne A. Epidemiological and medical aspects of epilepsy in the elderly. Epilepsy Res. 2006;68:S39-48.
  • [Cook et al., 2015] Cook M., Baker N., Lanes S., Bullock R., Wentworth C., Arrighi H.M. Incidence of stroke and seizure in Alzheimer's disease dementia. Age Ageing. 2015;44:695-699.
  • [Cretin et al., 2012] Cretin B., Blanc F., Gaultier C., Sellal F. Epileptic amnesic syndrome revealing Alzheimer's disease. Epilepsy Res. 2012;102:206-209.
  • [Cumbo and Ligori, 2010] Cumbo E., Ligori L.D. Levetiracetam, lamotrigine, and phenobarbital in patients with epileptic seizures and Alzheimer's disease. Epilepsy Behav. 2010;17:461-466.
  • [D’Orsi and Specchio, 2014] D’Orsi G., Specchio L.M. Progressive myoclonus epilepsy in Down Syndrome patients with dementia. J Neurol. 2014;261:1584-1597.
  • [Dubois et al., 2007] Dubois B., Feldman H.H., Jacova C. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734-746.
  • [Ezquerra et al., 1999] Ezquerra M., Carnero C., Blesa R., Gelpì J.L., Ballesta F., Oliva R. A presenilin 1 mutation (Ser169pro) associated with early-onset AD and myoclonic seizures. Neurology. 1999;52:566-570.
  • [Fisher et al., 2014] Fisher R.S., Acevedo C., Arzimanoglou A. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55:475-482.
  • [Forstl et al., 1992] Forstl H., Burns A., Levy R., Cairns N., Luthert P., Lantos P. Neurologic signs in Alzheimer's disease. Results of a prospective clinical and neuropathologic study. Arch Neurol. 1992;49:1038-1042.
  • [Fox et al., 1997] Fox N.C., Kennedy A.M., Harvey R.J. Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain. 1997;120:491-501.
  • [Garcia-Cabrero et al., 2013] Garcia-Cabrero A.M., Guerrero-Lopez R., Giraldez B.G. Hyperexcitability and epileptic seizures in a model of frontotemporal dementia. Neurobiol Dis. 2013;58:200-208.
  • [Greenberg et al., 2010] Greenberg S.M., Rapalino O., Frosch M.P. Case records of the Massachusetts General Hospital. Case 22-2010. An 87-year-old woman with dementia and a seizure. N Engl J Med. 2010;363:373-381.
  • [Guo et al., 1996] Guo Q., Furukawa K., Sopher B.L. Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide. Neuroreport. 1996;8:379-383.
  • [Hauser et al., 1986] Hauser W.A., Morris M.L., Heston L.L., Anderson V.E. Seizures and myoclonus in patients with Alzheimer's disease. Neurology. 1986;36:1226-1230.
  • [Hauser et al., 1996] Hauser W.A., Annegers J.F., Rocca W.A. Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester. Minnesota. Mayo Clin Proc. 1996;71:576-586.
  • [Hesdorffer et al., 1996] Hesdorffer D.C., Hauser W.A., Annegers J.F., Kokmen E., Rocca W.A. Dementia and adult-onset unprovoked seizures. Neurology. 1996;46:727-730.
  • [Heyman et al., 1987] Heyman A., Wilkinson W.E., Hurwitz B.J. Early-onset Alzheimer's disease: clinical predictors of institutionalization and death. Neurology. 1987;37:980-984.
  • [Iacopino and Christakos, 1990] Iacopino A.M., Christakos S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci USA. 1990;87:4078-4082.
  • [Imfeld et al., 2013] Imfeld P., Bodmer M., Schuerch M., Jick S.S., Meier C.R. Seizures in patients with Alzheimer's disease or vascular dementia: a population-based nested case-control analysis. Epilepsia. 2013;54:700-707.
  • [Irizarry et al., 2012] Irizarry M.C., Jin S., He F. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol. 2012;69:368-372.
  • [Lai and Williams, 1989] Lai F., Williams R.S. A prospective study of Alzheimer disease in Down syndrome. Arch Neurol. 1989;46:849-853.
  • [Larner, 2011] Larner A.J. Presenilin-1 mutation Alzheimer's disease: a genetic epilepsy syndrome? Epilepsy Behav. 2011;21:20-22.
  • [Larner and Doran, 2006] Larner A.J., Doran M. Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol. 2006;253:139-158.
  • [Letemendia and Pampiglione, 1958] Letemendia F., Pampiglione G. Clinical and electroencephalographic observations in Alzheimer's disease. J Neurochem. 1958;21:167-172.
  • [Liedorp et al., 2010] Liedorp M., Stam C.J., van der Flier W.M., Pijnenburg Y.A., Scheltens P. Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort. Dement Geriatr Cogn Disord. 2010;29:432-437.
  • [Lott et al., 2012] Lott I.T., Doran E., Nguyen V.Q., Tournay A., Movsesyan N., Gillen D.L. Down syndrome and dementia: seizures and cognitive decline. J Alzheimers Dis. 2012;29:177-185.
  • [Lozsadi and Larner, 2006] Lozsadi D.A., Larner A.J. Prevalence and causes of seizures at the time of diagnosis of probable Alzheimer's disease. Dement Geriatr Cogn Disord. 2006;22:121-124.
  • [McAreavey et al., 1992] McAreavey M.J., Ballinger B.R., Fenton G.W. Epileptic seizures in elderly patients with dementia. Epilepsia. 1992;33:657-660.
  • [Mendez et al., 1994] Mendez M.F., Catanzaro P., Doss R.C., R. A.R., Frey W.H. Seizures in Alzheimer's disease: clinicopathologic study. J Geriatr Psychiatry Neurol. 1994;7:230-233.
  • [Menéndez, 2005] Menéndez M. Down syndrome. Alzheimer's disease and seizures. Brain Dev. 2005;27:246-252.
  • [Minkeviciene et al., 2009] Minkeviciene R., Rheims S., Dobszay M.B. Amyloid beta-induced neuronal hyperexcitability triggers progressive epilepsy. J Neurosci. 2009;29:3453-3462.
  • [Nicastro et al., 2014] Nicastro N., Picard F., Assal F. Transient global amnesia mimics: transient epileptic amnesia. Epilepsy Behav Case Rep. 2014;2:100-101.
  • [Noebels, 2011] Noebels J.L. A perfect storm: converging paths of epilepsy and Alzheimer's dementia intersect in the hippocampal formation. Epilepsia. 2011;52:39-46.
  • [Palop and Mucke, 2009] Palop J.J., Mucke L. Epilepsy and cognitive impairments in Alzheimer disease. Arch Neurol. 2009;66:435-440.
  • [Palop et al., 2007] Palop J.J., Chin J., Roberson E.D. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron. 2007;55:697-711.
  • [Perkins, 2007] Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007;8:49-62.
  • [Picco et al., 2011] Picco A., Archetti S., Ferrara M. Seizures can precede cognitive symptoms in late-onset Alzheimer's disease. J Alzheimers Dis. 2011;27:737-742.
  • [Rabinowicz et al., 2000] Rabinowicz A.L., Starkstein S.E., Leiguarda R.C., Coleman A.E. Transient epileptic amnesia in dementia: a treatable unrecognized cause of episodic amnestic wandering. Alzheimer Dis Assoc Disord. 2000;14:231-233.
  • [Rao et al., 2009] Rao S.C., Dove G., Cascino G.D., Petersen R.C. Recurrent seizures in patients with dementia: frequency, seizure types, and treatment outcome. Epilepsy Behav. 2009;14:118-120.
  • [Ravizza and Vezzani, 2006] Ravizza T., Vezzani A. Status epilepticus induces time-dependent neuronal and astrocytic expression of interleukin-1 receptor type I in the rat limbic system. Neuroscience. 2006;137:301-308.
  • [Reitz et al., 2011] Reitz C., Brayne C., Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7:137-152.
  • [Risse et al., 1990] Risse S.C., Lampe T.H., Bird T.D. Myoclonus, seizures, and paratonia in Alzheimer disease. Alzheimer Dis Assoc Disord. 1990;4:217-225.
  • [Roberson et al., 2011a] Roberson E.D., Halabisky B., Yoo J.W. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neuroscience. 2011;31:700-711.
  • [Roberson et al., 2011b] Roberson E.D., Hope O.A., Martin R.C., Schmidt D. Geriatric epilepsy: research and clinical directions for the future. Epilepsy Behav. 2011;22:103-111.
  • [Romanelli et al., 1990] Romanelli M.F., Morris J.C., Ashkin K., Coben L.A. Advanced Alzheimer's disease is a risk factor for late-onset seizures. Arch Neurol. 1990;47:847-850.
  • [Rossi et al., 2013] Rossi C., De Herdt V., Dequatre-Ponchelle N., Hénon H., Leys D., Cordonnier C. Incidence and predictors of late seizures in intracerebral hemorrhages. Stroke. 2013;44:1723-1725.
  • [Saetre et al., 2007] Saetre E., Perucca A., Isojärvi J., Gjerstad L. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia. 2007;48:1292-1302. LAM 40089 Study Group
  • [Samson et al., 1996] Samson W.N., van Duijn C.M., Hop W.C., Hofman A. Clinical features and mortality in patients with early-onset Alzheimer's disease. Eur Neurol. 1996;36:103-106.
  • [Sanchez et al., 2012] Sanchez P.E., Zhu L., Verret L. Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model. Proc Natl Acad Sci USA. 2012;109:E2895-E2903.
  • [Santos et al., 2009] Santos S.F., Pierrot N., Morel N., Gailly P., Sindic C., Octave J.N. Expression of human amyloid precursor protein in rat cortical neurons inhibits calcium oscillations. J Neurosci. 2009;29:4708-4718.
  • [Scarmeas et al., 2009] Scarmeas N., Honig L.S., Choi H. Seizures in Alzheimer disease: who, when, and how common? Arch Neurol. 2009;66:992-997.
  • [Sherzai et al., 2014] Sherzai D., Losey T., Vega S., Sherzai A. Seizures and dementia in the elderly: Nationwide Inpatient Sample 1999-2008. Epilepsy Behav. 2014;36:53-56.
  • [Sjogren et al., 1952] Sjogren T., Sjogren H., Lindgren A.G. Morbus Alzheimer and morbus Pick; A genetic, clinical and patho-anatomical study. Acta Psychiatr Neurol Scand Suppl. 1952;82:1-152.
  • [Stefanits et al., 2014] Stefanits H., Wesseling C., Kovacs G.G. Loss of calbindin immunoreactivity in the dentate gyrus distinguishes Alzheimer's disease from other neurodegenerative dementias. Neurosci Lett. 2014;566:137-141.
  • [Sulkava, 1982] Sulkava R. Alzheimer's disease and senile dementia of Alzheimer type. A comparative study. Acta Neurol Scand. 1982;65:636-650.
  • [Tamagnini et al., 2015] Tamagnini F., Scullion S., Brown J.T., Randall A.D. Intrinsic excitability changes induced by acute treatment of hippocampal CA1 pyramidal neurons with exogenous amyloid beta peptide. Hippocampus. 2015;25:786-797.
  • [Volicer et al., 1995] Volicer L., Smith S., Volicer B.J. Effect of seizures on progression of dementia of the Alzheimer type. Dementia. 1995;6:258-263.
  • [Vossel et al., 2013] Vossel K.A., Beagle A.J., Rabinovici G.D. Seizures and epileptiform activity in the early stages of Alzheimer disease. JAMA Neurol. 2013;70:1158-1166.
  • [Werhahn et al., 2015] Werhahn K.J., Trinka E., Dobesberger J. A randomized, double-blind comparison of anti-epileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia. 2015;56:450-459.